All In Biotech

Drug Trial Radar · NCT04727034

Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy

A Multicenter, Randomized, Single-blind, Parallel Controlled Clinical Study on the Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy

Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,800

Planned (sponsor's estimate)

Start

Mar 2, 2021

Primary completion

Jul 1, 2023

Study completion Aug 1, 2023

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai East Hospital; Affiliated Hospital of Jiaxing University; The Second Affiliated Hospital of Jiaxing University; The First Affiliated Hospital of Nanchang University
First posted
Jan 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high. Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.

Conditions

  • Hypoxia
  • Gastric Cancer
  • Sedation Complication
  • Propofol Adverse Reaction

Interventions

  • Remimazolam tosylateDrug

    Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.

  • PropofolDrug

    Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The success rate of remazolam tosylate for sedation in gastroscopy diagnosis and treatmentTime frame: Patients will be followed for the duration of hospital stay, an expected average of 2 hours

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Jiaxing University

    Jiaxing, China · Recruiting

  • The Second Affifiliated Hospital of Jiaxing University

    Jiaxing, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Renji Hospital

    Shanghai, Shanghai, China, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai, China, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.